PMID- 17181921
OWN - NLM
STAT- MEDLINE
DCOM- 20070123
LR  - 20220227
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 24
IP  - 5
DP  - 2006 Sep-Oct
TI  - Regulation of serum chemokines following infliximab therapy in patients with 
      rheumatoid arthritis.
PG  - 529-33
AB  - OBJECTIVE: We studied the effects of the multiple infusions of infliximab, a 
      chimeric anti-tumor necrosis factor alpha (anti-TNF-alpha) antibody, on the serum 
      chemokines levels in patients with active rheumatoid arthritis (RA). METHODS: RA 
      patients were supposed to receive 9 infusions of infliximab (3mg/kg) at weeks 0, 
      2, 6, and every 8 weeks thereafter with the same dose. All patients continued 
      treatment with methotrexate (MTX) (7.5-20mg/week). Serum concentrations of 
      interleukin-8 (IL-8), RANTES (regulated upon activation, normal T cell expressed 
      and secreted) and monocyte chemoattractant protein-1 (MCP-1) were assessed by 
      ELISA at weeks 0, 2, 6, 14, 38, prior to infusion, and additionally at week 62. 
      RESULTS: Initial infusion of infliximab caused reduction in serum IL-8, RANTES 
      and MCP-1 (in all cases p < 0.001) levels. Subsequent infliximab administrations 
      also significantly decreased serum chemokines levels, but was less effective. 
      Prior to the first infliximab infusion serum concentrations of studied chemokines 
      correlated with markers of RA activity such as the erythrocyte sedimentation rate 
      (ESR) or CRP levels, number of swollen joints and disease activity score (DAS). 
      Following next drug infusions such associations were far less significant. 
      Infliximab treatment induced a significant reduction in the number of monocytes 
      observed through the whole study (in all cases p < 0.05). CONCLUSION: 
      Anti-TNF-alpha antibody therapy accompanied by MTX, beside a rapid clinical 
      improvement, reduced serum chemokines concentrations in RA patients. Subsequent 
      administrations of infliximab sustained chemokines decrease, although to a lesser 
      extent than the first two dose of infliximab.
FAU - Klimiuk, P A
AU  - Klimiuk PA
AD  - Department of Rheumatology and Internal Diseases, Medical University of 
      Bialystok, Bialystok, Poland. klimp@amb.edu.pl
FAU - Sierakowski, S
AU  - Sierakowski S
FAU - Domyslawska, I
AU  - Domyslawska I
FAU - Chwiecko, J
AU  - Chwiecko J
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Interleukin-8)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - Antirheumatic Agents/pharmacology/*therapeutic use
MH  - Arthritis, Rheumatoid/blood/*drug therapy/physiopathology
MH  - Blood Sedimentation
MH  - C-Reactive Protein/analysis
MH  - Chemokine CCL2/*blood
MH  - Chemokine CCL5/*blood
MH  - Humans
MH  - Infliximab
MH  - Interleukin-8/*blood
MH  - Joints/physiopathology
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Time Factors
EDAT- 2006/12/22 09:00
MHDA- 2007/01/24 09:00
CRDT- 2006/12/22 09:00
PHST- 2006/12/22 09:00 [pubmed]
PHST- 2007/01/24 09:00 [medline]
PHST- 2006/12/22 09:00 [entrez]
AID - 1932 [pii]
PST - ppublish
SO  - Clin Exp Rheumatol. 2006 Sep-Oct;24(5):529-33.